Literature DB >> 17537530

Effect of ppMCH derived peptides on PBMC proliferation and cytokine expression.

Bernard Coumans1, Thierry Grisar, Jean-Louis Nahon, Bernard Lakaye.   

Abstract

The mRNA encoding prepro-Melanin concentrating hormone (ppMCH) is mainly expressed in the central nervous system but has also been detected at lower amount in many peripheral tissues including spleen and thymus. At the peptide level however, several forms of the precursor can be detected in these tissues and are sometimes expressed at similar levels compared to brain. In the present work, we have studied the in vitro action of a wide range of concentration (1 nM to 1 microM) of the different peptides encoded by ppMCH i.e. neuropeptide glycine-glutamic acid (NGE), neuropeptide glutamic acid-isoleucine (NEI), Melanin concentrating hormone (MCH) and the dipeptide NEI-MCH on peripheral blood mononuclear cells (PBMC) proliferation and cytokine production following anti-CD3 stimulation. Among them only MCH decreased PBMC proliferation with a maximal effect of 35% at 100 nM. Moreover as demonstrated by using ELISA, MCH significantly decreases IL-2 production by 25% but not IL-4, INF-gamma or TNF-alpha expression. Interestingly, exogenous IL-2 decreases significantly MCH-mediated inhibition, suggesting that it is an important downstream mediator of MCH action. Finally, we showed that after 7 to 9 days of incubation, MCH also inhibits proliferation of non-stimulated PBMC. Altogether, these data demonstrate that fully mature MCH modulates proliferation of anti-CD3 stimulated PBMC partially through regulation of IL-2 production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537530     DOI: 10.1016/j.regpep.2007.04.001

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  Inflammation-induced functional connectivity of melanin-concentrating hormone and IL-10.

Authors:  Dimitrios C Ziogas; Apostolos K A Karagiannis; Brenda M Geiger; Beatriz Gras-Miralles; Robert Najarian; Ofer Reizes; Leo R Fitzpatrick; Efi Kokkotou
Journal:  Peptides       Date:  2014-02-18       Impact factor: 3.750

2.  Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis.

Authors:  Dimitrios C Ziogas; Beatriz Gras-Miralles; Sarah Mustafa; Brenda M Geiger; Robert M Najarian; Jutta M Nagel; Sarah N Flier; Yury Popov; Yu-Hua Tseng; Efi Kokkotou
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

3.  Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice.

Authors:  E Kokkotou; D O Espinoza; D Torres; I Karagiannides; S Kosteletos; T Savidge; M O'Brien; C Pothoulakis
Journal:  Gut       Date:  2008-09-29       Impact factor: 23.059

4.  Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.

Authors:  Shahryar Kiaii; Andrew J Clear; Alan G Ramsay; Derek Davies; Ajanthah Sangaralingam; Abigail Lee; Maria Calaminici; Donna S Neuberg; John G Gribben
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

5.  Increased susceptibility of melanin-concentrating hormone-deficient mice to infection with Salmonella enterica serovar Typhimurium.

Authors:  Apostolos K A Karagiannis; Dimitrios C Ziogas; Beatriz Gras-Miralles; Brenda M Geiger; Jutta Nagel; Estela Trebicka; Robert Najarian; Bobby J Cherayil; Efi Kokkotou
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

6.  Melanin-concentrating hormone as a mediator of intestinal inflammation.

Authors:  Efi Kokkotou; Alan C Moss; Daniel Torres; Iordanes Karagiannides; Adam Cheifetz; Sumei Liu; Michael O'Brien; Eleftheria Maratos-Flier; Charalabos Pothoulakis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

7.  PDGF Promotes Dermal Fibroblast Activation via a Novel Mechanism Mediated by Signaling Through MCHR1.

Authors:  Naoko Takamura; Ludivine Renaud; Willian Abraham da Silveira; Carol Feghali-Bostwick
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.